All markets data shared in the dashboard is copyright of GlobalData PLC and is subject to the GlobalData Terms & Conditions. Content in the dashboard should not be viewed as a recommendation and should not be relied upon to make investment decisions. We make every effort to ensure our content is accurate and to correct mistakes as soon as possible. If you spot an error please email editorialenquiries@globaldata.com. Further information about our editorial standards and complaints procedure is available here. GlobalData is not responsible for the use of any content outside the scope of the GlobalData Terms & Conditions.
Ampio Pharmaceuticals has obtained regulatory approval from the Drugs Controller General of India (DCGI) of the Central Drugs Standard Control Organization (CDSCO) to commence the…
Rhizen Pharmaceuticals has dosed the first subject in a Phase II clinical trial of its oral drug, RP7214, in Covid-19 patients with mild and symptomatic…
Roche has reported the latest results from the Phase III IMpower010 clinical trial where its Tecentriq (atezolizumab) offered substantial disease-free…
Clinical-stage biotech company Gritstone has dosed the first participants in a Phase I clinical trial of its second-generation, self-amplifying mRNA…
Landos Biopharma has signed a research partnership with the Icahn School of Medicine at Mount Sinai to carry out a…
Eiger BioPharmaceuticals has reported that the Data Safety Monitoring Board (DSMB) recommended continuing subject enrolment in the Peginterferon Lambda arm…
GlobalData exists to help businesses decode the future to profit from faster, more informed decisions.
© Copyright Verdict Media Limited 2021
